05
Feb

2014

Accelerating Medicines Partnership – Alzheimer’s disease

On February 4, 2014 the National Institutes of Health (NIH) announced the formation of the new Accelerating Medicines Partnership (AMP) to focus on three areas of research, including Alzheimer’s disease. This partnership, which brings together high level government entities, 10 biopharmaceutical companies and several non-profit organizations, is intended to identify and validate biomarkers of disease…more »

20
Sep

2013

An increasing call for including glia in the BRAIN mapping initiative

NIH neuroscientist Douglas Fields recently called for glia to be included in the BRAIN mapping initiative. The initiative, part of a new Presidential focus aimed at revolutionizing our understanding of the human brain, was announced in April 2013. The original intent of the project was to map out neuronal connections, but as Fields pointed out…more »

20
Sep

2013

GliaCure announces new CFO

GliaCure has recently been joined by Alan Barber of the Prestar Group as its CFO. Alan began his career as a CPA with Coopers & Lybrand. As a partner in Coopers Dallas and Tokyo offices his responsibilities included Mergers & Acquisitions Practice Leader for the Southwest Region and Partner-in-Charge of the Foreign Financial Services practice…more »

05
Sep

2013

Glia’s role in schizophrenia

A group from the Netherlands has recently reported on a likely role for glia in schizophrenia susceptibility. Based on studies that glial cells play a significant role in synaptic transmission the group carried out a a functional gene set analysis to test for the combined effects of genetic variants in glial type-specific genes for association with…more »

09
May

2013

New publication supports GliaCure’s approach to depression

A manuscript published in the May 5 edition of Nature Medicine documents research findings that stimulating endogenous ATP release from astrocytes induces antidepressant-like effects in mouse models of depression. The authors summarize their study by stating that: “Understanding the mechanisms that underlie the antidepressant-like effect of ATP may allow the identification of new targets for…more »

19
Mar

2013

New study by Haydon lab indicates that astrocytes play a role in stroke

A new study recently published by GliaCure President Phil Haydon’s research lab at Tufts University indicates that astrocytes play a vital role in the spread of damage after stroke. This study, published in The Journal of Neuroscience, suggests that, while researchers have previously focused on the role of neurons and their release of neurotransmitters in…more »

04
Feb

2013

President Phil Haydon’s recent findings reported in BioWorld

GliaCure President Phil Haydon’s recent findings on the role of glia in sleep disorders and depression were reported today in the industry publication BioWorld. http://www.bioworld.com/content/support-cells-star-lack-sleeps-antidepressant-effects

30
Jan

2013

Haydon lab publishes work on role of astrocytes in depression

GliaCure President Phil Haydon’s research laboratory at Tufts University has published a study showing that glia may provide the key to a novel treatment for depression. It has long been known that a total night of sleep deprivation has a fast-acting antidepressant effect; however, the mechanism underlying this effect was not understood. The Haydon group…more »

16
Dec

2012

NIDA highlights new publication co-authored by Phil Haydon

In its reports on Latest Science the National Institute of Drug Abuse (NIDA) highlighted an upcoming publication co-authored by GliaCure President Phil Haydon. Haydon and his collaborators at the University of Pennsylvania have discovered that glia likely play a key role in relapse of individuals addicted to cocaine. Glia may thus provide a target for…more »

Page 3 of 5